Generation Bio Co (GBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Generation Bio Co (GBIO) has a cash flow conversion efficiency ratio of -1.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-52.68 Million) by net assets ($50.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Generation Bio Co (GBIO) balance sheet quality index to measure how much of total assets are equity-financed.
Generation Bio Co - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Generation Bio Co's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Generation Bio Co cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Generation Bio Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Generation Bio Co ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beaconsmind AG
PA:MLBMD
|
-1.608x |
|
Yuanta Securities Korea Co Ltd Preference Shares
KO:003475
|
-0.087x |
|
Sheh Kai Precision Co Ltd
TWO:2063
|
0.067x |
|
Lotte Chilsung Beverage Co Ltd
KO:005305
|
0.033x |
|
Boer Power Holdings Limited
F:BOE
|
0.201x |
|
Estrella Resources Ltd
AU:ESR
|
-0.064x |
|
Dynamic Precision Industry
TWO:8928
|
-0.251x |
|
FRANCHETTI S.P.A.
F:D0E
|
N/A |
Annual Cash Flow Conversion Efficiency for Generation Bio Co (2018–2024)
The table below shows the annual cash flow conversion efficiency of Generation Bio Co from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Generation Bio Co stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $86.20 Million | $-88.56 Million | -1.027x | -295.65% |
| 2023-12-31 | $203.13 Million | $-52.74 Million | -0.260x | +28.40% |
| 2022-12-31 | $282.49 Million | $-102.45 Million | -0.363x | -50.77% |
| 2021-12-31 | $381.75 Million | $-91.82 Million | -0.241x | +8.09% |
| 2020-12-31 | $268.01 Million | $-70.14 Million | -0.262x | -163.95% |
| 2019-12-31 | $-98.59 Million | $-40.35 Million | 0.409x | -39.47% |
| 2018-12-31 | $-41.59 Million | $-28.12 Million | 0.676x | -- |
About Generation Bio Co
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise me… Read more